Trust and Transparency: Patient Perceptions of Physicians' Financial Relationships with Pharmaceutical Companies

Journal of Law, Medicine and Ethics

Volumn 42, Issue 4, 2014, Pages 475-491

  Perry, Joshua E ^a   Cox, Dena ^a   Cox, Anthony D ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFLICT OF INTEREST; DRUG INDUSTRY; ECONOMICS; HUMAN; INTERPERSONAL COMMUNICATION; PHYSICIAN; TRUST; UNITED STATES;

CONFLICT OF INTEREST; DISCLOSURE; DRUG INDUSTRY; HUMANS; PHYSICIANS; TRUST; UNITED STATES;

EID: 84921690908     PISSN: 10731105     EISSN: 1748720X     Source Type: Journal    
DOI: 10.1111/jlme.12169     Document Type: Article

References (50)

1. B. Lo and M. J. Field, eds., Conflict of Interest in Medical Research, Education, and Practice (Washington, D.C.: The National Academies Press, 2009) (hereinafter COI)
2. E. G. Campbell et al., "A National Survey of Physician-Industry Relationships," New England Journal of Medicine 356, no. 17 (2007): 1742-1750
3. M. A. Morgan et al., "Interactions of Doctors with the Pharmaceutical Industry," Journal of Medical Ethics 32, no. 10 (2006): 559-563
4. S. Sismondo, "Key Opinion Leaders and the Corruption of Medical Knowledge: What the Sunshine Act Will and Won't Cast Light On," Journal of Law, Medicine & Ethics 41, no. 3 (2013): 635-643
5. I. Gorlach and G. Pham-Kanter, "Brightening Up: The Effect of the Physician Payment Sunshine Act on Existing Regulation of Pharmaceutical Marketing," Journal of Law, Medicine & Ethics 41, no. 1 (2013): 315-322
6. P. Loftus, "Doctors Face New Scrutiny over Gifts," Wall Street Journal, August 23, 2013
7. E. D. Pellegrino and A. S. Relman, "Professional Medical Associations: Ethical and Practical Guidelines," JAMA 282, no. 10 (1999): 984-986
8. A. S. Kesselheim and D. Orentlicher, "Insights from a National Conference: 'Conflicts of Interest in the Practice of Medicine,'" Journal of Law, Medicine & Ethics 40, no. 3 (2012): 436-440
9. M. A. Rodwin, "Conflicts of Interest, Institutional Corruption, and Pharma: An Agenda for Reform," Journal of Law, Medicine & Ethics 40, no. 3 (2012): 511-522
10. E. G. Campbell, "Doctors and Drug Companies: Scrutinizing Influential Relationships," New England Journal of Medicine 357, no. 18 (2007): 1796-1797
11. T. A. Brennan et al., "Health Industry Practices That Create Conflicts of Interest: A Policy Proposal for Academic Medical Centers," JAMA 295, no. 4 (2006): 429-433
12. R. Adair and L. Holmgren, "Do Drug Samples Influence Resident Prescribing Behavior? A Randomized Trial," American Journal of Medicine 118, no. 8 (2005): 881-884
13. N. Mizik and R. Jacobson, "Are Physicians 'Easy Marks'? Quantifying the Effects of Detailing and Sampling on New Prescriptions," Management Science 50, no. 12 (2004): 1704-1715
14. S. M. Keim, M. Z. Mays, and D. Grant, "Interactions between Emergency Medicine Programs and the Pharmaceutical Industry," Academic Emergency Medicine 11, no. 1 (2004): 19-26
15. T. E. Finucane and C. E. Boult, "Association of Funding and Findings of Pharmaceutical Research at a Meeting of a Medical Professional Society," American Journal of Medicine 117, no. 11 (2004): 842-845
16. D. Blumenthal, "Doctors and Drug Companies," New England Journal of Medicine 351, no. 18 (2004): 1885-1890
17. A. S. Brett, W. Burr, and J. Moloo, "Are Gifts From Pharmaceutical Companies Ethically Problematic? A Survey of Physicians," Archives of Internal Medicine 163, no. 18 (2003): 2213-2218
18. A. Wazana, "Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?" JAMA 283, no. 3 (2000): 373-380
19. T. S. Caudill, et al., "Physicians, Pharmaceutical Sales Representatives, and the Cost of Prescribing," Archives of Family Medicine 5, no. 4 (1996): 201-206
20. M. M. Chren and C. S. Landefeld, "Physicians' Behavior and Their Interactions with Drug Companies: A Controlled Study of Physicians Who Requested Additions to a Hospital Drug Formulary," JAMA 271, no. 9 (1994): 684-689
21. J. P. Orlowski and L. Wateska, "The Effects of Pharmaceutical Firm Enticements on Physician Prescribing Patterns: There's No Such Thing as a Free Lunch," Chest 102, no. 1 (1992): 270-273
22. N. Lurie et al., "Pharmaceutical Representatives in Academic Medical Centers: Interaction with Faculty and Housestaff," Journal of General Internal Medicine 5, no. 3 (1990): 240-243
23. J. Avorn, M. Chen, and R. Hartley, "Scientific Versus Commercial Sources of Influence on the Prescribing Behavior of Physicians," American Journal of Medicine 73, no. 1 (1982): 4-8
24. Medicare Payment Advisory Commission, Report to Congress: Medicare Payment Policy 21 (March 17, 2009)
25. See 153 Cong. Rec. 11,217-18 (2007) (Senator Grassley speaking on the Senate floor describing the need for greater transparency regarding industry payments and the importance of this issue for all Americans who take prescription drugs or use medical devices)
26. 154 Cong. Rec. 2,320 (2008) (Senator Grassley discussing the influence of industry payments over physician decision making)
27. 155 Cong. Rec. 787-88 (2009) (Senators Grassley and Kohl discussing their hope that the Sunshine Act serve as a catalyst for patients to discuss with their physician any concerns about improper financial relationships and noting their attempt to balance "legitimate" industry payments to physicians for research, as well as industry's right to spend an unlimited amount of money on marketing their products)
28. A. Stamatoglou, "The Physician Payment Sunshine Act: An Important First Step in Mitigating Financial Conflicts of Interest in Medical and Clinical Practice," John Marshall Law Review 45, no. 3 (2012): 963-1008
29. M. J. Green et al., "Do Gifts from the Pharmaceutical Industry Affect Trust in Physicians?" Family Medicine 44, no. 5 (2012): 325-31
30. M. A. Hall and C. E. Schneider, "Patients as Consumers: Courts, Contracts, and the New Medical Marketplace," Michigan Law Review 106, no. 4 (2008): 643
31. M. A. Hall et al., "Trust in Physicians and Medical Institutions: What Is It, Can It Be Measured, and Does It Matter?" Millbank Quarterly 79, no. 4 (2001): 613-639
32. S. D. Pearson and L. H. Raeke, "Patients' Trust in Physicians: Many Theories, Few Measures, and Little Data," Journal of General Internal Medicine 15, no. 7 (2000): 509-513
33. D. Mechanic, "The Functions and Limitations of Trust in the Provision of Medical Care," Journal of Health Politics, Policy, and Law 23, no. 4 (1998): 661-687
34. D. Grande, J. A. Shea, and K. Armstrong, "Pharmaceutical Industry Gifts to Physicians: Patient Beliefs and Trust in Physicians and the Health Care System," Journal of General Internal Medicine 27, no. 3 (2011): 274-279
35. Centers for Medicare and Medicaid Services, "Open Payments User Guide for Industry" (July 2013)
36. G. Loewenstein, S. Sah, and D. M. Cain, "The Unintended Consequences of Conflict of Interest Disclosure," Journal of the American Medical Association 307, no. 7 (2012): 669-670
37. S. D. Pearson et al., "A Trial of Disclosing Physicians' Financial Incentives to Patients," Archives of Internal Medicine 166, no. 6 (2006): 623-628
38. R. E. Herzlinger, Market-Driven Health Care (Reading, MA: Perseus Books, 1997): 290-291
39. M. E. Porter and E. O. Teisberg, Redefining Health Care (Boston: Harvard Business School Press, 2006): 83-84
40. S. L. Cutrona et al., "Characteristics of Recipients of Free Prescription Drug Samples: A Nationally Representative Analysis," American Journal of Public Health 98, no. 2 (2008): 284-289
41. (last visited November 5, 2014)
42. J. Ritchie and L. Spencer, "Qualitative Data Analysis for Applied Policy Research," in A. Bryman and R. Burgess, eds., Analysing Qualitative Data (London: Routledge, 1994): at 172-194
43. G. Leydon et al., "Cancer Patients' Information Needs and Information Seeking Behavior: In Depth Interview Study," British Medical Journal, 320, no. 7239 (2000): 909-924.
44. R. K. Merton and P. Kendall, "The Focused Interview," American Journal of Sociology, 51, no. 6 (1946): 541-557
45. G. Keppel and T. D. Wickens, Design and Analysis: A Researcher's Handbook (Upper Saddle, NJ: Pearson, 2004)
46. J. Cohen, Statistical Power Analysis in the Behavioral Sciences (Hillsdale, NJ: Erlbaum, 1988)
47. D. Shear, "Inside the Race to Rescue a Health Care Site, and Obama," New York Times, November 30, 2013.
48. J. M. Donohue et al., "A Decade of Direct-to-Consumer Advertising of Prescription Drugs," New England Journal of Medicine 357, no. 7 (2007): 673-681
49. Centers for Medicare and Medicaid Services, "Open Payments User Guide for Industry" (July 2013)
50. M. Lamkin and C. Elliott, "Curing the Disobedient Patient: Medication Adherence Programs as Pharmaceutical Marketing Tools," Journal of Law, Medicine & Ethics 42, no. 4 (2014): 492-500